Team

MaxiVAX team

Dimitrios Goundis, Ph.D. - CEO

Previously Head of R&D for The Medicines Company, COO of Speedel (acquired by Novartis in 2008) and Roche

Nicolas Mach, M.D. - CSO

A co-founder of MaxiVAX and a pioneer in the field of Immuno-Oncology. Currently he is Deputy Head of Oncology at the University Hospital of Geneva (HUG) and Head of the Clinical Research Unit at the same hospital.

Toni Perez, M.D. - Medical Director 

Dr. Perez has spent over 30 years in the Pharma industry in different management positions within Research & Development, including Novartis, Biogen and The Medicines Company.

Julien Grogg - Director of Clinical Operations

Mr.  Grogg worked previously at Anecova a private biotech company based in Lausanne (Switzerland) where he was responsible for the R&D and manufacturing activities.

Suzanne du Pasquier – Office Manager

Previously worked in the banking and financial industry for over 15 years as assistant to relationship managers.

Xavier Luria, M.D. - EU Regulatory Strategy

Dr. Luria studied internal pharmaceutical medicine and biostatistics. He was Head of Safety and Efficacy at the European Medicines Agency (EMA) during 2005-2012, and previously held leadership positions in the biopharmaceutical industry for more than 18 years, covering international clinical development, pharmacovigilance, biostatistics and medical affairs.

Cindy Dinella - US Regulatory Strategy

Founding partner and President of Advyzom – a consulting company specializing in highly strategic regulatory & development advice. Dr Dinella worked at Hoffmann-La Roche Inc. as Vice President of Drug Regulatory Affairs (2001-2011).

Steve Pikulin, Ph.D, RAC -  US Regulatory Strategy

President of TechReg Services Inc. since 1999. Previously held various positions in the pharmaceutical industry in Drug Discovery, Manufacturing Operations, Analytical Research, Quality Control, Quality Assurance and CMC Regulatory Affairs.

Ivor Elrifi, Ph.D. - Intellectual Property

Dr. Ivor Elrifi is the chair of Cooley's patent counselling and prosecution practice group. He advises pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world, particularly in the US and Europe

Board of Directors

The members of the Board of Directors are Bernard Mach as the Executive Chairman, Clarence Peter (a partner of the law firm Python) and Jack Barbut (ex-CEO of NovImmune).